XML 22 R10.htm IDEA: XBRL DOCUMENT v3.24.3
SEGMENTS
9 Months Ended
Sep. 30, 2024
Segment Reporting [Abstract]  
SEGMENTS

4. SEGMENTS

 

Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision–making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision-maker is the CEO. The Company operates in and reports four business segments: real estate, digital transformation technology, biohealth, and other business activities. The Company’s reportable segments are determined based on the services they perform and the products they sell, not on the geographic area in which they operate. The Company’s chief operating decision maker evaluates segment performance based on segment revenue. Costs excluded from segment income (loss) before taxes and reported as “Other” consist of corporate general and administrative activities which are not allocable to the four reportable segments.

 

The following table summarizes the Company’s segment information for the following balance sheet dates presented, and for the nine months ended September 30, 2024 and 2023:

 

   Real Estate   Digital Transformation Technology   Biohealth Business   Other   Total 
                     
Nine Months Ended on September 30, 2024                         
Revenue  $10,997,704   $-   $-   $1,176,260   $12,173,964 
Cost of Sales   (7,882,274)   -    (3,409)   (552,466)   (8,438,149)
Gross Profit (Loss)   3,115,430    -    (3,409)   623,794    3,735,815 
Operating Expenses   (1,321,120)   (421,543)   (910,354)   (7,122,562)   (9,775,579)
Operating Income (Loss)   1,794,310    (421,543)   (913,763)   (6,498,768)   (6,039,764)
Other Income (Expense)   11,784    (1,935,969)   (923,595)   1,893,028    (954,752)
Net Income (Loss) Before Income Tax   1,806,094    (2,357,512)   (1,837,358)   (4,605,740)   (6,994,516)

 

 

   Real Estate   Digital Transformation Technology   Biohealth Business   Other   Total 
                     
Nine Months Ended on September 30, 2023                         
Revenue  $20,227,362   $28,094   $12,786   $802,741   $21,070,983 
Cost of Sales   (12,755,702)   (9,145)   (21,516)   (222,470)   (13,008,833)
Gross Profit (Loss)   7,471,660    18,949    (8,730)   580,271    8,062,150 
Operating Expenses   (1,418,743)   (327,746)   (638,738)   (4,734,061)  $(7,119,288)
Operating Income (Loss)   6,052,917    (308,797)   (647,468)   (4,153,790)   942,862 
Other Income (Expense)   58,635    36,855    (223,570)   (27,932,254)  $(28,060,334)
Net Income (Loss) Before Income Tax   6,111,552    (271,942)   (871,038)   (32,086,044)   (27,117,472)
                          
September 30, 2024                         
Cash and Restricted Cash  $4,044,262   $407,297   $400,244   $12,775,024   $17,626,826 
Total Assets   63,266,446    3,760,853    2,755,291    29,006,247    98,788,837 
                          
December 31, 2023                         
Cash and Restricted Cash  $3,323,210   $430,807   $568,702   $23,566,574   $27,889,293 
Total Assets   62,989,233    5,845,269    2,450,876    55,028,650   $126,314,028